Johannes Jacob Pieter Kastelein - Aug 21, 2025 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Role
Chief Scientific Officer, Director
Signature
/s/ Louise Kooij by Power of Attorney for Johannes Jacob Pieter Kastelein
Stock symbol
NAMS
Transactions as of
Aug 21, 2025
Transactions value $
-$2,471,640
Form type
4
Date filed
8/25/2025, 05:04 PM
Previous filing
Mar 28, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kastelein Johannes Jacob Pieter Chief Scientific Officer, Director C/O NEWAMSTERDAM PHARMA COMPANY N.V., GOOIMEER 2-35, NAARDEN, NETHERLANDS /s/ Louise Kooij by Power of Attorney for Johannes Jacob Pieter Kastelein 2025-08-25 0002000389

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NAMS Ordinary Shares Sale -$1.21M -50K -29.53% $24.29 119K Aug 21, 2025 See footnote F1, F2
transaction NAMS Ordinary Shares Sale -$1.06M -42.3K -35.49% $25.08 77K Aug 22, 2025 See footnote F2, F3
transaction NAMS Ordinary Shares Sale -$195K -7.66K -9.95% $25.49 69.3K Aug 22, 2025 See footnote F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.73 per share to $24.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F2 The ordinary shares are held by Futurum B.V. ("Futurum") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the ordinary shares held by Futurum.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.39 per share to $25.35 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.39 per share to $25.62 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.